Overview

A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

Status:
Not yet recruiting
Trial end date:
2025-05-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS
Phase:
Phase 1
Details
Lead Sponsor:
QurAlis Corporation